FDG-PET for management of cervical and ovarian cancer

Gynecologic Oncology

Volumn 97, Issue 1, 2005, Pages 183-191

  Havrilesky, Laura J ^a   Kulasingam, Shalini L ^b,c   Matchar, David B ^a,c,d   Myers, Evan R ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Cervical cancer; Ovarian cancer; Positron emission tomography

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE;

CANCER DIAGNOSIS; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER;

EID: 15544384862     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.12.007     Document Type: Article

References (46)

1. L.L. Subak, H. Hricak, and C.B. Powell Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging Obstet. Gynecol. 86 1 1995 43 50
2. D. Matchar, S. Kulasingam, L. Havrilesky, L. Mann, E. Myers, and D. McCrory Evidence report for positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular) 2004 Agency for Healthcare Research and Quality
3. D.G. Fryback, and J.R. Thornbury The efficacy of diagnostic imaging Med. Decis. Mak. 11 2 1991 88 94
4. J.J. Deeks Systematic reviews of evaluations of diagnostic screening tests M. Egger G.D. Smith D.G. Altman Systematic reviews in health care. Meta-analysis in context 2001 BMJ Publishing Group London, England 248 282
5. C.B. Begg, and M. Mazumdar Operating characteristics of a rank correlation test for publication bias Biometrics 50 4 1994 1088 1101
6. M. Egger, G. Davey Smith, and M. Schneider Bias in meta-analysis detected by a simple, graphical test BMJ 315 7109 1997 629 634
7. M.J. Reinhardt, C. Ehritt-Braun, and D. Vogelgesang Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET Radiology 218 3 2001 776 782
8. P.G. Rose, L.P. Adler, and M. Rodriguez Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study J. Clin. Oncol. 17 1 1999 41 45
9. W.C. Lin, Y.C. Hung, and L.S. Yeh Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings Gynecol. Oncol. 89 1 2003 73 76
10. L.S. Yeh, Y.C. Hung, and Y.Y. Shen Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings Oncol. Rep. 9 6 2002 1289 1292
11. Y. Sugawara, A. Eisbruch, and S. Kosuda Evaluation of FDG PET in patients with cervical cancer J. Nucl. Med. 40 7 1999 1125 1131
12. T. Belhocine, A. Thille, and V. Fridman Contribution of whole-body 18FDG PET imaging in the management of cervical cancer Gynecol. Oncol. 87 1 2002 90 97
13. P.W. Grigsby, B.A. Siegel, and F. Dehdashti Lymph node staging by positron emission tomography in patients with carcinoma of the cervix J. Clin. Oncol. 19 17 2001 3745 3749
14. T.R. Miller, E. Pinkus, and F. Dehdashti Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer J. Nucl. Med. 44 2 2003 192 197
15. D.H.K.K. Park, S.Y. Park, B.H. Lee, C.W. Choi, and S.Y. Chin Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography Korean J. Radiol. 1 1 2000 51 55
16. S.Y. Ryu, M.H. Kim, and S.C. Choi Detection of early recurrence with 18F-FDG PET in patients with cervical cancer J. Nucl. Med. 44 3 2003 347 352
17. Y. Nakamoto, A. Eisbruch, and E.D. Achtyes Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy Gynecol. Oncol. 84 2 2002 289 295
18. S.S. Sun, T.C. Chen, and R.F. Yen Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer Anticancer Res. 21 4B 2001 2957 2961
19. W.C. Chang, Y.C. Hung, and C.C. Lin Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels-a preliminary report Cancer Invest. 22 2 2004 180 184
20. P.W. Grigsby, B.A. Siegel, and F. Dehdashti Posttherapy surveillance monitoring of cervical cancer by FDG-PET Int. J. Radiat. Oncol., Biol., Phys. 55 4 2003 907 913
21. C.H. Lai, K.G. Huang, and L.C. See Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-d-glucose positron emission tomography Cancer 100 3 2004 544 552
22. P.G. Rose, P. Faulhaber, and F. Miraldi Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy Gynecol. Oncol. 82 1 2001 17 21
23. T. Torizuka, S. Nobezawa, and T. Kanno Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d- glucose Eur. J. Nucl. Med. Mol. Imaging 29 6 2002 797 803
24. Y. Nakamoto, T. Saga, and T. Ishimori Clinical value of positron emission tomography with FDG for recurrent ovarian cancer AJR Am. J. Roentgenol. 176 6 2001 1449 1454
25. M. Zimny, W. Siggelkow, and W. Schroder 2-[Fluorine-18]-fluoro-2-deoxy-d- glucose positron emission tomography in the diagnosis of recurrent ovarian cancer Gynecol. Oncol. 83 2 2001 310 315
26. S.M. Cho, H.K. Ha, and J.Y. Byun Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer AJR Am. J. Roentgenol. 179 2 2002 391 395
27. B.Y. Karlan, R. Hawkins, and C. Hoh Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-d-glucose can detect recurrent ovarian carcinoma Gynecol. Oncol. 51 2 1993 175 181
28. W.C. Chang, Y.C. Hung, and C.H. Kao Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker Neoplasma 49 5 2002 329 333
29. J. Jimenez-Bonilla, A. Maldonado, and S. Morales Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels Clin. Positron Imaging 3 6 2000 231 236
30. R.F. Yen, S.S. Sun, and Y.Y. Shen Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer Anticancer Res. 21 5 2001 3691 3694
31. K.F. Hubner, T.W. McDonald, and J.G. Niethammer Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG) Gynecol. Oncol. 51 2 1993 197 204
32. L. Portelance, K.S. Chao, and P.W. Grigsby Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation Int. J. Radiat., Oncol. Biol. Phys. 51 1 2001 261 266
33. P.B. Heller, J.H. Maletano, and B.N. Bundy Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for paraaortic node metastasis-a Gynecologic Oncology Group study Gynecol. Oncol. 38 3 1990 425 430
34. S.H. Kim, B.I. Choi, and J.K. Han Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients J. Comput. Assist. Tomogr. 17 4 1993 633 640
35. S.H. Kim, S.C. Kim, and B.I. Choi Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging Radiology 190 3 1994 807 811
36. J. Scheidler, H. Hricak, and K.K. Yu Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis JAMA 278 13 1997 1096 1101
37. R.A. Lawhead Jr., D.G. Clark, and D.H. Smith Pelvic exenteration for recurrent or persistent gynecologic malignancies: a 10-year review of the Memorial Sloan-Kettering Cancer Center experience (1972-1981) Gynecol. Oncol. 33 3 1989 279 282
38. G.W. Morley, M.P. Hopkins, and S.M. Lindenauer Pelvic exenteration, University of Michigan: 100 patients at 5 years Obstet. Gynecol. 74 6 1989 934 943
39. F.N. Rutledge, J.P. Smith, and J.T. Wharton Pelvic exenteration: analysis of 296 patients Am. J. Obstet. Gynecol. 129 8 1977 881 892
40. M.L. Gemignani, K.M. Alektiar, and M. Leitao Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers Int. J. Radiat., Oncol. Biol. Phys. 50 3 2001 687 694
41. M.M. Leitao Jr., and D.S. Chi Recurrent cervical cancer Curr. Treat. Opt. Oncol. 3 2 2002 105 111
42. J.N. Buy, A.A. Moss, and M.A. Ghossain Peritoneal implants from ovarian tumors: CT findings Radiology 169 3 1988 691 694
43. F.V. Coakley, P.H. Choi, and C.A. Gougoutas Peritoneal metastases: detection with spiral CT in patients with ovarian cancer Radiology 223 2 2002 495 499
44. L. Prayer, C. Kainz, and J. Kramer CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer J. Comput. Assist. Tomogr. 17 4 1993 626 632
45. R.E. Bristow, M.G. del Carmen, and H.K. Pannu Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT Gynecol. Oncol. 90 3 2003 519 528
46. H.K. Pannu, C. Cohade, and R.E. Bristow PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation Abdom. Imaging 18 2004 18